ADMA Biologics (NASDAQ:ADMA) Shares Up 8.8% – Time to Buy?

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) shot up 8.8% on Monday . The company traded as high as $21.18 and last traded at $21.11. 4,282,141 shares were traded during trading, an increase of 20% from the average session volume of 3,567,260 shares. The stock had previously closed at $19.40.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Performance

The company has a market capitalization of $5.17 billion, a P/E ratio of 77.78 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average is $17.96 and its two-hundred day moving average is $18.19.

Institutional Trading of ADMA Biologics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. National Bank of Canada FI purchased a new stake in ADMA Biologics during the third quarter valued at about $35,000. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics in the 4th quarter valued at about $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics during the 4th quarter worth approximately $51,000. Finally, Farther Finance Advisors LLC raised its holdings in ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 2,505 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.